| Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. EMA Tannock IF1, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S ... N Engl J Med. 351 (15), 1502-12, 2004 | 7446* | 2004 |
| Increased survival with enzalutamide in prostate cancer after chemotherapy HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R De Wit, ... New England Journal of Medicine 367 (13), 1187-1197, 2012 | 5417 | 2012 |
| Abiraterone and increased survival in metastatic prostate cancer JS De Bono, CJ Logothetis, A Molina, K Fizazi, S North, L Chu, KN Chi, ... New England Journal of Medicine 364 (21), 1995-2005, 2011 | 5207 | 2011 |
| The immune landscape of cancer V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ... Immunity 48 (4), 812-830. e14, 2018 | 4987 | 2018 |
| Enzalutamide in metastatic prostate cancer before chemotherapy TM Beer, AJ Armstrong, DE Rathkopf, Y Loriot, CN Sternberg, CS Higano, ... New England Journal of Medicine 371 (5), 424-433, 2014 | 3542 | 2014 |
| Abiraterone in metastatic prostate cancer without previous chemotherapy CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ... New England Journal of Medicine 368 (2), 138-148, 2013 | 3328 | 2013 |
| An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ... Cell 173 (2), 400-416. e11, 2018 | 3027 | 2018 |
| Oncogenic signaling pathways in the cancer genome atlas F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ... Cell 173 (2), 321-337. e10, 2018 | 2818 | 2018 |
| The molecular taxonomy of primary prostate cancer A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, ... Cell 163 (4), 1011-1025, 2015 | 2807 | 2015 |
| Comprehensive characterization of cancer driver genes and mutations MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ... Cell 173 (2), 371-385. e18, 2018 | 2408 | 2018 |
| Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. CKN Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY ... N Engl J Med. 377 (4), 352-360, 2017 | 2317* | 2017 |
| Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ... Cell 173 (2), 291-304. e6, 2018 | 2266 | 2018 |
| A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma F Saad, DM Gleason, R Murray, S Tchekmedyian, P Venner, L Lacombe, ... Journal of the National Cancer Institute 94 (19), 1458-1468, 2002 | 2135 | 2002 |
| Olaparib for metastatic castration-resistant prostate cancer J de Bono, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 382 (22), 2091-2102, 2020 | 2041 | 2020 |
| Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer O Sartor NEJM 385 (12), 1091-1103, 2021 | 1881 | 2021 |
| Machine learning identifies stemness features associated with oncogenic dedifferentiation TM Malta, A Sokolov, AJ Gentles, T Burzykowski, L Poisson, JN Weinstein, ... Cell 173 (2), 338-354. e15, 2018 | 1831 | 2018 |
| Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo … K Fizazi, HI Scher, A Molina, CJ Logothetis, KN Chi, RJ Jones, ... The lancet oncology 13 (10), 983-992, 2012 | 1762 | 2012 |
| Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall … CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ... The Lancet Oncology 16 (2), 152-160, 2015 | 1649 | 2015 |
| Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer F Saad, DM Gleason, R Murray, S Tchekmedyian, P Venner, L Lacombe, ... Journal of the National Cancer Institute 96 (11), 879-882, 2004 | 1524 | 2004 |
| Apalutamide treatment and metastasis-free survival in prostate cancer MR Smith, F Saad, S Chowdhury, S Oudard, BA Hadaschik, JN Graff, ... New England Journal of Medicine 378 (15), 1408-1418, 2018 | 1455 | 2018 |
Kim N. ChiProfessor of Medicine, University of British ColumbiaVerified email at bccancer.bc.ca
